Drug Trial Radar · NCT05186818
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM
Last checked: Nov 20, 2026Latest source record: Mar 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
282
Actual
Start
Feb 1, 2022
Primary completion
Nov 10, 2023
Study completion Dec 18, 2023
Sponsor
- Lead sponsor
- CytokineticsIndustry
- Sponsor type
- Industry
- Collaborators
- Corxel Pharmaceuticals
- First posted
- Jan 11, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of aficamten (CK-3773274) versus placebo in adults with symptomatic hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract obstruction.
Conditions
- Obstructive Hypertrophic Cardiomyopathy (oHCM)
Interventions
Aficamten (5 mg, 10 mg, 15 mg, and 20 mg)Drug
Aficamten tablets were administered orally once daily.
Placebo to match aficamtenDrug
Placebo tablets were administered orally once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in pVO2 at Week 24Time frame: Baseline to Week 24
Locations
114 sites in 14 countries. Site status is shown where the registry gives one.
Alaska Heart and Vascular Institute
Anchorage, Alaska
UC San Diego Health - Sulpizio Cardiovascular Center
La Jolla, California
Cedars-Sinai Medical Center - Smidt Heart Institute Clinic
Los Angeles, California
University of California San Francisco
San Francisco, California
Stanford University Hospital
Stanford, California
Yale School of Medicine
New Haven, Connecticut
Yale University School of Medicine
New Haven, Connecticut
MedStar Washington Hospital Center
Washington D.C., District of Columbia
Holy Cross Hospital / Cardiology Associates
Fort Lauderdale, Florida
Mayo Clinic Florida
Jacksonville, Florida
Emory Clinic
Atlanta, Georgia
Piedmont Fayette Hospital
Fayetteville, Georgia
Northwestern University
Chicago, Illinois
University of Iowa
Iowa City, Iowa
MedStar Medical Group Cardiology at Union Memorial
Baltimore, Maryland
Medstar Franklin Square Medical Center
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts
Lahey Hospital & Medical Center
Burlington, Massachusetts
Michigan Medicine
Ann Arbor, Michigan
Henry Ford Medical Center
Detroit, Michigan
Spectrum Health Medical Group Cardiovascular Medicine
Grand Rapids, Michigan
M Health Fairview University of Minnesota Medical Center - East Bank
Minneapolis, Minnesota
Mayo Clinic
Rochester, Minnesota
Saint Luke's Hospital of Kansas City
Kansas City, Missouri
Washington University School of Medicine
St Louis, Missouri
Morristown Medical Center
Morristown, New Jersey
NYU Langone Health
New York, New York
Mount Sinai Hospital
New York, New York
Columbia University Medical Center/NY Presbyterian Hospital
New York, New York
Westchester Medical Center
Valhalla, New York
Sanger Heart and Vascular Institute
Charlotte, North Carolina
Sanger Heart and Vascular Institute - HCM Clinic
Charlotte, North Carolina
Duke Health Center Arringdon
Morrisville, North Carolina
Cleveland Clinic
Cleveland, Ohio
The Ohio State University Wexner Medical Center
Columbus, Ohio
Ascension St. John Clinical Research Institute
Tulsa, Oklahoma
Oregon Health & Science University
Portland, Oregon
Hospital of the University of Pennsylvania (University of Pennsylvania School of Medicine)
Philadelphia, Pennsylvania
UPMC Presbyterian
Pittsburgh, Pennsylvania
Showing 40 of 114 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.